



NDA 18-956/S-058

Amersham Health
Attention: Paula Clark
Associate, Regulatory Affairs
101 Carnegie Center
Princeton, NJ 08540

Dear Ms. Clark:

Please refer to your supplemental new drug application dated January 16, 2004, received January 20, 2004, submitted under section 505(b)/pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Omnipaque™ (Iohexol) Injection.

We acknowledge receipt of your submissions of January 15 and 30, 2004.

Your submission of January 30, 2004, constituted a complete response to our January 7, 2004, action letter.

This supplemental new drug application provides for the addition of the phrase "in +PLUS PAK™ (polymer bottle)" to the immediate container labels, the secondary labels and the package insert for Omnipaque™ Injection in the polypropylene container closure system.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to submitted labeling (package insert submitted January 30, 2004, immediate container labels submitted September 18, 2003, and carton labels submitted January 16, 2004).

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 18-956/S-058." Approval of this submission by FDA is not required before the labeling is used.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Medical Imaging and Radiopharmaceutical Drug Products and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call James Moore, Regulatory Project Manager, at (301) 827-6254.

Sincerely,

{See appended electronic signature page}

Eldon Leutzinger, Ph.D.
Chemistry Team Leader for the
Division of Medical Imaging and
Radiopharmaceutical Drug Products
(HFD-160)
DNDCII, Office of New Drug Chemistry
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Eldon Leutzinger
3/5/04 01:37:45 PM